Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model
Authors:
- 1 September 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 36 (9) , 914-921
Abstract
Objective(18)F-Fluorodeoxyglucose (F-18-FDG), F-18-fluoro-3-deoxy-3-l-fluorothymidine (F-18-FLT), F-18-fluoromisonidazole (F-18-FMISO), and F-18-AlF-NOTA-PRGD2 (F-18-RGD) are all commonly used PET tracers for tumor diagnosis based on different mechanisms of tissue uptake. This study compared the ex-vivo biodistribution and PET/computed tomography (CT) imaging studies of these four PET tracers in a xenograft prostate tumor-bearing mouse model.Materials and methodsNude mice were inoculated with 5x10(6) PC-3 cells in the right armpit. The ex-vivo biodistribution of F-18-FDG, F-18-FLT, F-18-FMISO, and F-18-RGD at 30, 60, 90, and 120min after injection was compared. Micro-PET/CT images of F-18-FDG, F-18-FLT, and F-18-RGD were acquired at 60min, whereas F-18-FMISO images were acquired at 90min after injection.ResultsThe tumors were clearly visualized by micro-PET/CT using all four PET tracers. Ex-vivo biodistribution results showed highest tumor accumulation and tumor-to-muscle ratio of F-18-FDG at each time point, accompanied by physiologically high uptakes in the brain, heart, and intestinal tract. Modest uptake of F-18-FLT and F-18-FMISO in tumors was observed at 60 and 90min after injection, with less interference from other tissues compared with F-18-FDG. Besides, F-18-RGD also exhibited high tumor specificity; however, relatively low uptake was observed in the tumor.ConclusionOur results demonstrated the potential of F-18-FMISO and F-18-FLT in the diagnosis of xenograft prostate cancer. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.Keywords
This publication has 42 references indexed in Scilit:
- Evaluation of 188Re-MAG2-RGD-bombesin for potential prostate cancer therapyNuclear Medicine and Biology, 2013
- RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone MetastasisCancers, 2012
- PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2European Journal of Nuclear Medicine and Molecular Imaging, 2012
- PET/CT Imaging and Radioimmunotherapy of Prostate CancerSeminars in Nuclear Medicine, 2011
- 18F-FPPRGD2 and 18F-FDG PET of Response to Abraxane TherapyJournal of Nuclear Medicine, 2010
- Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7–14)NH2], in a prostate tumor xenografted mouse modelNuclear Medicine and Biology, 2010
- Comparison of 18F-FET and 18F-FDG PET in brain tumorsNuclear Medicine and Biology, 2009
- Improving Tumor Uptake and Pharmacokinetics of 64Cu-Labeled Cyclic RGD Peptide Dimers with Gly3 and PEG4 LinkersBioconjugate Chemistry, 2009
- Evaluation of anesthesia effects on [18F]FDG uptake in mouse brain and heart using small animal PETNuclear Medicine and Biology, 2004
- Detection of bony metastases of androgen-independent prostate cancer by PET-FDGNuclear Medicine and Biology, 1996